Lv21
150 积分 2024-09-04 加入
Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
2小时前
待确认
国内不同类型下尿路感染患者尿路病原菌构成及药敏分析的多中心研究
4天前
已完结
Frontline treatment options for higher-risk MDS: can we move past azacitidine?
9天前
已关闭
Frontline treatment options for higher-risk MDS: can we move past azacitidine?
9天前
已关闭
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
9天前
已完结
Azacitidine (AZA) is effective treatment for myelodysplastic syndromes (MDS) at a dosing schedule of 75 mg/m(2)/d subcutaneously for 7 days every 4 weeks. The initial phase of this ongoing multicenter, community-based, open-label study evaluated three alternative AZA dosing schedules without weekend dosing
1个月前
已完结
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
1个月前
已完结
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
1个月前
已关闭
[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)]
1个月前
已完结
皖公网安备34019202002308
